A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin G4 Related Disease

Interventions

DRUG: Rilzabrutinib
DRUG: Placebo
DRUG: Glucocorticoid

Sponsor

Sanofi